Advanced search
Publication Cover
Scandinavian Journal of Urology and Nephrology Volume 30, 1996 - Issue 5
Submit an article Journal homepage
49
Views
27
CrossRef citations to date
0
Altmetric
Urology: Original clinical scientific reports

Placebo Effects in the Pharmacological Treatment of Uncomplicated Benign Prostatic Hyperplasia

Bo Jesper Hansen The Department of Urology, Bispebjerg Hospital, Denmark.
,
Hans Henrik Meyhoff Department of Surgery A, Section of Urology, Hillerød Hospital, Denmark.
,
Jørgen Nordling The Department of Urology, Herlev Hospital, Denmark.
,
Han Ja Mensink The Department of Urology, Academic Hospital, Groningen, The Netherlands.
,
Peter Mogensen The Department of Urology, Bispebjerg Hospital, Denmark.
&
Erik Højkjær Larsen The Department of Urology, Aalborg Hospital, Denmark.
Pages 373-377 | Received 10 Aug 1995, Accepted 27 Sep 1995, Published online: 15 Feb 2010

REFERENCES

  • Aso Y, Boccon-Gibod L, Calais Da Silva F, et al. Subjective response, objective response, impact on quality of life. In: Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S & Murphy G, eds. The International Consultation on Benign Prostatic Hyperplasia (BPH). Geneva: WHO, 1991: 87–90.
  • Balslev Jørgensen J, Jensen KM-E, Mogensen P. Longitudinal observations on normal and abnormal voiding in men over the age of 50 years. Br J Urol 1993; 72: 413–420.
  • Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 495–506.
  • Beecher HK. The powerful placebo. JAMA 1955; 159: 1602–1606.
  • Birkhoff JD, Wiederhorn AR, Hamilton ML, Zinsser HH. Natural history of benign prostatic hypertrophy and acute retention. Urology 1976; 7: 48–52
  • Brody H. The lie that heals: The ethics of giving placebos. Ann Intern Med 1982; 97: 112–118.
  • Bruskewitz RC, Iversen P, Madsen PO. Value of postvoid residual urine determination in evaluation of prostatism. Urology 1982; 20: 602–608.
  • Duncan BM, Garraway WM. Prostatic surgery for Benign prostatic hyperplasia: Meeting the expanding demand. Br J Urol 1993; 72: 761–765.
  • The finasteride study group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291–299.
  • Fischer HK, Dlin BM. The dynamics of placebo therapy: A clinical study. Am J Med Sci 1956; 232: 504–512.
  • Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hyperplasia in the community. Lancet 1991; 338: 469–471.
  • Garraway WM, Armstrong C, Auld S, King S, Simpson RJ. Follow-up of a cohort of men with untreated benign prostatic hyperplasia. Eur Urol 1993; 24: 313–318.
  • Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–1191.
  • Hansen BJ, Nordling J, Mensink HJA, Walter S, Meyhoff HH and The ALFECH study group. Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. Scand J Urol Nephrol 1994; (Suppl 157): 169–175.
  • Jardin A, Bensadoun H, Delauche-Cavaillier MC, Attali P, and The BPH-ALF Group. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457–1461.
  • Kleijnen J, de Craen AJM, van Everdingen J, Krol L. Placebo effect in double-blind clinical trials: a review of interactions with medications. Lancet 1994; 344: 1347–1349.
  • Lasagna L, Laties VG, Dohan JL. Further studies on the “pharmacology” of placebo administration. J Clin Invest 1958; 37: 533–537.
  • Lepor H, Laddu A. Terazosin in the treatment of benign prostatic hyperplasia: The United States Experience. Br J Urol 1992; 70 (Suppl 1): 2–9.
  • Lindahl O, Lindwall L. Is all therapy just placebo effect? Metamedicine 1982; 3: 255–259.
  • Madsen PO, Iversen P. A point system for selecting operative candidates. In: Hinman FJr, ed., Benign prostatic hypertrophy. New York: Springer Verlag, 1983: 763–765.
  • Roehrborn CG. The assessment of medical treatment for benign prostatic hyperplasia. In: Kurth K, Newling DWW, eds. EORTC Genitourinary Group Monograph. 12. Benign prostatic hyperplasia, recent progress in clinical research and practice. New York: Wiley-Liss 1994; PCBR 386: 175–190.
  • Sommer P, Nielsen KK, Bauer T, et al. Voiding patterns in men evaluated by a questionnaire survey. Br J Urol 1990; 65: 155–160.
  • Wein AJ. Evaluation of treatment response in benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 631–640.
  • Wolf S. Effects of suggestion and conditioning on the action of chemical agents in human objects—the pharmacology of placebos. J Clin Invest 1950; 29: 100–109.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.